(R)-Cinacalcet-D3

(S)-Cinacalcet-D3 is a deuterated version of the medication Cinacalcet, used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease and hypercalcemia in patients with parathyroid carcinoma. The deuterium substitution in (S)-Cinacalcet-D3 allows for better identification and quantification of the drug in biological samples during clinical trials. The chemical formula of (S)-Cinacalcet-D3 is C22H21D3F2N and it has a molecular weight of 346.45 g/mol. It works by binding to the calcium-sensing receptor on the parathyroid gland, which reduces the secretion of parathyroid hormone and decreases serum calcium levels. The recommended dosage of (S)-Cinacalcet-D3 varies depending on the individual patient's needs and medical condition. It is typically taken orally, with or without food, once daily. The drug should be used with caution in patients with moderate to severe hepatic impairment, as it can increase the risk of adverse effects. (S)-Cinacalcet-D3 is generally well-tolerated, but some side effects may occur. These can include nausea, vomiting, diarrhea, headache, and dizziness. Patients should inform their healthcare provider if they experience any adverse effects while taking the medication. Overall, (S)-Cinacalcet-D3 is a useful medication for the treatment of hyperparathyroidism and hypercalcemia. Its deuterated form allows for more accurate measurement and analysis during clinical trials, which can lead to improved drug development and patient outcomes.